Trial · NCT04010539
Results by group218
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 218
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8) | Gepotidacin | Microbiological success | 187 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8) | Ceftriaxone Plus Azithromycin | Microbiological success | 186 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8) | Gepotidacin | Microbiological failure, BP | 0 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8) | Ceftriaxone Plus Azithromycin | Microbiological failure, BP | 0 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8) | Gepotidacin | Microbiological failure, UTD | 15 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8) | Ceftriaxone Plus Azithromycin | Microbiological failure, UTD | 18 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Rectal Site at the TOC Visit | Gepotidacin | Microbiological success | 26 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Rectal Site at the TOC Visit | Ceftriaxone Plus Azithromycin | Microbiological success | 12 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Rectal Site at the TOC Visit | Gepotidacin | Microbiological failure, BP | 0 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Rectal Site at the TOC Visit | Ceftriaxone Plus Azithromycin | Microbiological failure, BP | 0 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Rectal Site at the TOC Visit | Gepotidacin | Microbiological failure, UTD | 0 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Rectal Site at the TOC Visit | Ceftriaxone Plus Azithromycin | Microbiological failure, UTD | 3 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Pharyngeal Site at the TOC Visit | Gepotidacin | Microbiological success | 14 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Pharyngeal Site at the TOC Visit | Ceftriaxone Plus Azithromycin | Microbiological success | 16 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Pharyngeal Site at the TOC Visit | Gepotidacin | Microbiological failure, BP | 2 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Pharyngeal Site at the TOC Visit | Ceftriaxone Plus Azithromycin | Microbiological failure, BP | 0 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Pharyngeal Site at the TOC Visit | Gepotidacin | Microbiological failure, UTD | 2 | Participants | |
| Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Pharyngeal Site at the TOC Visit | Ceftriaxone Plus Azithromycin | Microbiological failure, UTD | 1 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) and Any Serious Adverse Events (SAEs) | Gepotidacin | Any TEAEs | 230 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) and Any Serious Adverse Events (SAEs) | Ceftriaxone Plus Azithromycin | Any TEAEs | 104 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04010539/results